Quick Facts

• Erectile Dysfunction: Helps support the capacity to achieve and maintain an erection.
• Pulmonary Arterial Hypertension (PAH): Used to promote exercise ability and help manage clinical worsening in adults.

Sildenafil is an established treatment approved for two primary therapeutic domains. The first use is to address erectile dysfunction, where the medication helps to support the capacity to achieve and maintain an erection sufficient for sexual activity. It assists in restoring impaired erectile function when sexual stimulation occurs.

The second principal use is for the management of Pulmonary Arterial Hypertension (PAH), a type of high blood pressure that impacts the arteries in the lungs. In this context, Sildenafil is administered to help promote exercise ability and delay clinical worsening in adult patients. It supports pulmonary blood flow, which may reduce the workload on the heart. The medication is also utilized in pediatric patients (ages 1 to 17) for this same indication. Both main uses are approved indications.

Regulatory References

1. NIH MedlinePlus guidance

Sildenafil is a prescription medication with strictly defined eligibility criteria outlined in regulatory documents for both its uses: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

Absolute Contraindications (Must Not Use)

Condition/Population	Restriction Status
Concomitant use with Organic Nitrates or Riociguat	Contraindicated (Risk of severe hypotension)
History of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)	Contraindicated (For the ED indication)
Severe Hepatic Impairment (Child-Pugh Class C)	Contraindicated (Safety not established)
Recent history of stroke or myocardial infarction	Contraindicated
Known Hypersensitivity to sildenafil or its components	Contraindicated

Official Eligibility and Restrictions

Population	Eligibility Rule
Adult Men (ge 18 years)	Approved for ED indication.
Adults and Children (1–17 years)	Approved for PAH indication.
Infants (< 1 year)	Use not established or recommended.
Severe Renal Impairment (ED use)	Conditional use; cautious dose selection may be required.
PVOD or Sickle Cell PAH	Use not recommended (Risk of worsening condition).

Eligibility is also restricted for men for whom sexual activity is medically inadvisable due to underlying cardiovascular status.

The official interaction profile for Sildenafil is defined by two primary mechanisms documented in regulatory sources: additive blood pressure lowering effects (pharmacodynamic) and metabolic interference (pharmacokinetic).

Interaction Classifications (High-Level)

Interaction severity classification: Contraindicated (with Nitrates and Riociguat), Clinically Significant (with CYP3A4 inhibitors and alpha-blockers).

---

Official Interaction Statements

• Co-administration is contraindicated with Organic Nitrates and the guanylate cyclase stimulator Riociguat due to the confirmed potentiation of hypotensive effects.
• Strong CYP3A4 Inhibitors (e.g., Ritonavir, Ketoconazole) increase Sildenafil plasma concentrations (reduced clearance) as metabolism is primarily mediated by CYP3A4.
• A formal regulatory requirement restricts the maximum Sildenafil dose to 25 mg within 48 hours when co-administered with Ritonavir.
• The co-administration of Sildenafil and alpha-blockers may result in an additive blood pressure lowering effect. Official documents require patients to be hemodynamically stable on alpha-blocker therapy prior to Sildenafil initiation.
• The consumption of a high-fat meal may delay the medicine's absorption and onset of action.
• Reduced clearance and increased systemic exposure are documented in patients with hepatic impairment.

---

Connection to the overall interaction profile

Regulatory documents define the Sildenafil interaction structure through two primary axes: absolute contraindication due to additive pharmacodynamic effects (hypotension risk), and restrictions stemming from the pharmacokinetic effect of reduced clearance when co-administered with strong CYP enzyme inhibitors. This structure establishes mandatory administration constraints based strictly on the documented changes in Sildenafil exposure or the risk of combined cardiovascular effects.

Sildenafil operates via a precise, peripheral molecular mechanism, targeting the regulation of vascular smooth muscle tone and requiring a natural physiological trigger.

Selective Inhibition of the PDE5 Enzyme

Sildenafil functions as a highly selective inhibitor of the enzyme Phosphodiesterase type 5 (PDE5), which is abundant in specific arterial smooth muscle cells. By blocking PDE5, the drug prevents the rapid breakdown of the secondary messenger cyclic guanosine monophosphate (cGMP). This molecular mechanism facilitates the accumulation of cGMP, sustaining its concentration within the cell.

Signal Amplification and Vasodilation

The mechanism is Nitric Oxide (NO)-dependent, requiring the initial release of NO from local cells to initiate the relaxation cascade. Sildenafil's inhibition of PDE5 acts as a signal amplifier, significantly prolonging and potentiating the transient NO signal. This sustained activation leads to a cellular cascade that reduces intracellular calcium concentration, causing smooth muscle relaxation. The physiological consequence of this relaxation is vasodilation, which significantly reduces local vascular resistance and allows for an increased volume of blood flow into the affected region.

Official Sildenafil Administration Guidelines

Sildenafil usage follows distinct protocols for its two primary indications, requiring strict adherence to the administration route, timing, and dosage. The medication is available for oral administration across both indications, though an intravenous (IV) form is also approved for use in Pulmonary Arterial Hypertension (PAH).

Dosing and Scheduling

Usage Entity	Erectile Dysfunction (ED)	Pulmonary Arterial Hypertension (PAH)
Route of Administration	Oral tablet	Oral tablet/suspension or IV injection
Dosing Schedule	Intermittent use as needed, with a starting dose of 50 mg (ranging 25 mg to 100 mg).	Continuous use on a three-times-daily (TID) schedule.
Administration Timing	Approximately one hour before anticipated activity. May be taken with or without food, but high-fat meals can affect absorption.	Doses should be administered at fixed intervals, typically four to six hours apart.
Maximum Frequency	Once per day.	Three times per day.

Population-Specific Instructions

Official prescribing information outlines specific dosing adjustments for vulnerable patient populations. A lower 25 mg starting dose for ED is typically considered for older adults (age ge 65 years) and individuals with severe renal or hepatic impairment due to altered drug clearance. For PAH treatment in pediatric patients (ages 1 to 17), dosing is based on the patient's body weight. For patients receiving PAH treatment, the IV formulation (10 mg) is procedurally equivalent to the 20 mg oral dose when transitioning between administration methods. This ensures the standardized approach to medication use.

Research Evidence / Overview of Studies for Sildenafil

Evidence for use in Erectile Dysfunction (ED)

The research conducted for sildenafil in erectile dysfunction (ED) consists of short-term, randomized, double-blind, placebo-controlled trials (RCTs). These trials were applied in studies examining patient-reported experiences and how symptoms changed over time. The studies primarily evaluated adult men with ED stemming from various causes, including those with underlying conditions like diabetes.

Research highlights changes measured during the study period related to the capacity to achieve and maintain an erection, as documented by patient self-assessment questionnaires. Findings describe patterns observed in the studies where patients reported changes in outcomes related to their daily functioning or activity level. Studies monitored outcomes related to episodic or acute changes in erectile function.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

The research conducted for sildenafil in pulmonary arterial hypertension (PAH) consists of randomized, placebo-controlled trials. These short-term trials were supported by long-running open-label extension studies that continued to monitor patients for several years. The PAH research examined outcomes reflecting daily functioning or activity level in conditions marked by functional limitations.

Studies monitored changes in exercise capacity, primarily by measuring the distance patients could walk in six minutes (the 6-Minute Walk Distance). Additionally, research monitored outcomes capturing phases of heightened symptom activity, specifically the time to clinical worsening events (such as hospitalization or the initiation of new PAH therapy).

Long-Term Studies and Follow-Up Data

When considering both indications, the available research indicates that the pivotal short-term RCTs served as the basis for regulatory review. Since those initial trials, long-term open-label extension studies were conducted, particularly in the context of PAH, with some observation periods extending for 3 years or more.

However, despite these longer-running studies, long-term effects are not fully established regarding patterns observed in survival when the medicine was used alone for PAH. Follow-up durations were limited in some cohorts, meaning certainty remains low when drawing conclusions about effects lasting many decades.

What is Still Uncertain About Sildenafil Research

The research landscape, while extensive, contains gaps and areas where certainty remains low. The initial research for ED included a limited follow-up duration in the pivotal trials. A significant limitation for the PAH indication is that the main measure of effectiveness, the 6-Minute Walk Distance, can be subjective because it is an effort-dependent measure.

Key Studies & References NIH MedlinePlus: Sildenafil Drug Information (Used for regulatory context)

Common questions about Sildenafil (FAQ)

Q: Why is Sildenafil sometimes referred to by a different name?

A: Sildenafil is the active chemical compound, which is formulated as sildenafil citrate salt. Official documents indicate the medication may be marketed under different trade names, often depending on the country or the specific medical condition it is approved to treat, such as pulmonary arterial hypertension or erectile dysfunction.

Q: Is Sildenafil safe for older adults?

A: Official prescribing information indicates that a lower starting dose is typically considered for older adults aged 65 years and over. This approach is considered because regulatory documents note that drug clearance may be altered in this population, necessitating a cautious administration approach.

Q: Is Sildenafil available over the counter in some places?

A: According to official regulatory documentation, Sildenafil is classified as a prescription-only (Rx) medication. The official classification requires authorization from a licensed healthcare professional for the medication to be dispensed.

Q: What is the difference between brand-name Sildenafil and generic Sildenafil?

A: Official documents confirm the medication's active chemical compound is sildenafil citrate. The generic form contains the identical active ingredient as the brand-name version. Both forms are subject to the same regulatory standards for manufacturing and quality.

Q: Is there a maximum number of times Sildenafil can be taken within a week?

A: The maximum recommended frequency for administration depends on the condition being managed. For erectile dysfunction, official guidelines state that the medication should be taken no more than once per day. For the continuous treatment of pulmonary arterial hypertension, it is administered up to three times per day.

Q: Can women use Sildenafil for any condition?

A: Official regulatory documentation approves Sildenafil for the treatment of pulmonary arterial hypertension (PAH) in adults, which includes women. However, it is not indicated or approved for use by women for the erectile dysfunction indication.

Q: Are there official studies on the safety of Sildenafil for young adults?

A: Research conducted for the erectile dysfunction indication primarily involved adult men aged 18 years and older. Therefore, the clinical data used for regulatory review includes the younger adult population.

Q: Is Sildenafil considered an aphrodisiac?

A: According to the official mechanism of action, Sildenafil is Nitric Oxide-dependent and requires a natural physiological trigger, such as sexual stimulation, to work. This indicates that the medication is not described in official literature as causing or increasing sexual arousal or desire independently of a physiological trigger.

Q: Can Sildenafil be taken on an empty stomach?

A: Official administration guidelines state that the medication can be taken with or without food. Regulatory documents note that taking it on an empty stomach may allow the medication to be absorbed more quickly by the body than taking it with a heavy or high-fat meal.

Q: What should be done if someone misses a dose of Sildenafil (in the context of pulmonary hypertension)?

A: Prescribing information defines a strict, continuous three-times-daily (TID) schedule for the pulmonary arterial hypertension indication. This defined schedule describes the required adherence to fixed administration intervals as outlined by regulatory authorities.

Q: What happens in the body to cause the potential side effect of nasal congestion with Sildenafil?

A: The function of the medication involves promoting vasodilation, which is the widening of blood vessels. This effect is consistent with the physiological changes associated with the medication, which can include adverse reactions like nasal congestion as commonly reported in official labeling.

Q: Does Sildenafil have an impact on fertility or sperm count?

A: Studies that have examined the effect of a single dose on measures of sperm function in healthy volunteers reported finding no statistically significant adverse effects.

Q: What is the typical time frame that the effects of Sildenafil last?

A: The maximum therapeutic effect of Sildenafil is generally documented to occur within one to two hours after administration. Following a single dose, the effect is expected to be sustained for a period of a few hours.

Q: Is Sildenafil a controlled substance?

A: Sildenafil is classified by regulatory bodies as a prescription-only (Rx) medication. This medication is not listed as a federally controlled substance.

Q: Does alcohol consumption impact the effectiveness of Sildenafil?

A: Official regulatory warnings note that the consumption of alcohol may increase the risk of certain side effects, such as headache and flushing. Additionally, alcohol may further potentiate the drug's blood pressure-lowering effect.

Q: Can Sildenafil cause dizziness or lightheadedness?

A: Dizziness is listed in official documentation as a potential adverse reaction. This symptom is often referenced in official information in connection with the drug's action of promoting vasodilation and its resulting blood pressure-lowering effect.

Q: Does Sildenafil interact with common herbal supplements?

A: Regulatory information advises that many herbal remedies and supplements are not tested for interactions in the same way as prescription medications. Due to this difference in testing, the co-administration of herbal remedies and Sildenafil is a matter noted in regulatory guidance.

Q: Does Sildenafil interact with medicines for high cholesterol?

A: Official documentation references high cholesterol as an underlying vascular risk factor often present in individuals who experience a rare adverse reaction (NAION). However, regulatory warnings do not identify cholesterol medications as belonging to a formal, defined interaction class.

Q: Are there any known interactions between Sildenafil and recreational drugs?

A: Sildenafil is strictly contraindicated for co-administration with any form of nitrates or nitric oxide donors. This contraindication covers nitrates found in recreational drugs, such as amyl nitrite or 'poppers.'

How to Store and Dispose of Sildenafil? (Official Regulatory Information)

---

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Avoid excessive heat and do not freeze.
Protection	Keep the medication in its original container, tightly closed, to protect it from moisture and strong light.
Pediatric Safety	Keep out of the reach of children and store locked up to prevent accidental ingestion.

---

Disposal Instructions

Sildenafil is not on the official flush list; therefore, it should not be poured down a sink or toilet. The preferred method for disposal is utilizing a community drug take-back program. If such a program is unavailable, unused medication should be mixed with an unpalatable substance (like used coffee grounds) and placed in a sealed container before being thrown into the household trash. For the oral suspension, discard any unused portion after 60 days from the date it was reconstituted.